FindTrial
Sign In

Ivonescimab Combined With Chemotherapy

DRUG6 trials

Sponsors

Sun Yat-sen University, Jiangsu Province Nanjing Brain Hospital, Tianjin Medical University Cancer Institute and Hospital, The First Hospital of Jilin University, Women's Hospital School Of Medicine Zhejiang University

Conditions

AK112ChemotherapyEGFR-TKIEsophageal Squamour Cell CancerFirst-line TreatmentKRAS G12C Lung CancerLOCALLY ADVANCED CERVICAL CANCERSLeptomeningeal Metastases

Phase 2

Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial
Not yet recruitingNCT06750952
Sun Yat-sen UniversityFirst-line Treatment, Relapsed or Metastatic Thymic Cancer
Start: 2024-12-20End: 2028-12-20Target: 24Updated: 2024-12-27
Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer
Not yet recruitingNCT06814158
Tianjin Medical University Cancer Institute and HospitalEsophageal Squamour Cell Cancer
Start: 2025-03-01End: 2026-12-31Target: 57Updated: 2025-02-07
Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma
RecruitingNCT06875076
The First Hospital of Jilin UniversityPretreated Pleural Mesothelioma
Start: 2025-03-08End: 2029-12-31Target: 25Updated: 2025-03-13
Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer
Not yet recruitingNCT07244965
Women's Hospital School Of Medicine Zhejiang UniversityLOCALLY ADVANCED CERVICAL CANCERS
Start: 2025-12-01End: 2029-07-01Target: 42Updated: 2025-11-24
Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)
Not yet recruitingNCT07472478
Guangdong Provincial People's HospitalKRAS G12C Lung Cancer, Lung Cancer (NSCLC)
Start: 2026-03-15End: 2028-03-31Target: 32Updated: 2026-03-16

Unknown Phase

Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs
Not yet recruitingNCT06766591
Jiangsu Province Nanjing Brain HospitalAK112, Chemotherapy, EGFR-TKI +2
Start: 2025-01-01End: 2025-10-31Target: 36Updated: 2025-01-09